BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

• US 20170096495A1
• Filed: 09/29/2016
• Published: 04/06/2017
• Est. Priority Date: 10/02/2015
• Status: Abandoned Application

• Current Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Original Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Inventors: HOFER, Thomas, NAYAK, Tapan, BACAC, Marina, IMHOF-JUNG, Sabine, KLEIN, Christian, KLOSTERMANN, Stefan, MOLHOJ, Michael, REGULA, Joerg Thomas, SCHAEFER, Wolfgang, UMAA, Pablo, WEINZIERL, Tina
• Application Number:
  US15/279,738
• Publication Number:
  US 20170096495A1
• Time in Patent Office: Days
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/35 Valency
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/522 CH1 domain
• CPC Class Codes: C07K 2317/526 CH3 domain
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/64 comprising a combination of variable region and constant region components
• CPC Class Codes: C07K 2317/66 comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
• CPC Class Codes: C07K 2317/71 Decreased effector function due to an Fc-modification
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Claims

1. A T cell activating bispecific antigen binding molecule comprising:

(a) a first antigen binding moiety which specifically binds to a first antigen;

(b) a second antigen binding moiety which specifically binds to a second antigen;

wherein the first antigen is an activating T cell antigen and the second antigen is STEAP-1, or the first antigen is STEAP-1 and the second antigen is an activating T cell antigen; and

wherein the antigen binding moiety which specifically binds to STEAP-1 comprises a heavy chain variable region, particularly a humanized heavy chain variable region, comprising the heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO;

14, the HCDR 2 of SEQ ID NO;

15 and the HCDR 3 of SEQ ID NO;

16, and a light chain variable region, particularly a humanized light chain variable region, comprising the light chain complementarity determining region (LCDR) 1 of SEQ ID NO;

17, the LCDR 2 of SEQ ID NO;

18 and the LCDR 3 of SEQ ID NO;

19.

2. The T cell activating bispecific antigen binding molecule according to claim 1, wherein the antigen binding moiety which specifically binds to STEAP-1 comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:

20 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO;

21.

3. The T cell activating bispecific antigen binding molecule according to claim 1, wherein the antigen binding moiety which specifically binds to STEAP-1 comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:

32, and a light chain variable region comprising the amino acid sequence of SEQ ID NO;

21.

5. The T cell activating bispecific antigen binding molecule according to claim 1, wherein the second antigen binding moiety is a Fab molecule which specifically binds to a second antigen, and wherein the variable domains VL and VH or the constant domains CL and CH1 of the Fab light chain and the Fab heavy chain are replaced by each other.

6. The T cell activating bispecific antigen binding molecule according to claim 1, wherein the activating T cell antigen is CD3.

7. The T cell activating bispecific antigen binding molecule according to claim 1, wherein the activating T cell antigen is CD3 epsilon.

8. The T cell activating bispecific antigen binding molecule according to claim 1, wherein the antigen binding moiety which specifically binds to the activating T cell antigen comprises the heavy chain complementarity determining region (CDR) 1 of SEQ ID NO:

4, the heavy chain CDR 2 of SEQ ID NO;

5, the heavy chain CDR 3 of SEQ ID NO;

6, the light chain CDR 1 of SEQ ID NO;

8, the light chain CDR 2 of SEQ ID NO;

9 and the light chain CDR 3 of SEQ ID NO;

10.

9. The T cell activating bispecific antigen binding molecule according to claim 1, wherein the antigen binding moiety which specifically binds to the activating T cell antigen comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:

3 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO;

7.

10. The T cell activating bispecific antigen binding molecule according to claim 1, wherein the first antigen binding moiety under (a) is a first Fab molecule which specifically binds to a first antigen, the second antigen binding moiety under (b) is a second Fab molecule which specifically binds to a second antigen wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other;

and

i) in the constant domain CL of the first Fab molecule under a) the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and wherein in the constant domain CH1 of the first Fab molecule under a) the amino acid at position 147 or the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index);

or

ii) in the constant domain CL of the second Fab molecule under b) the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and wherein in the constant domain CH1 of the second Fab molecule under b) the amino acid at position 147 or the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index).

13. The T cell activating bispecific antigen binding molecule according to claim 10, wherein in the constant domain CL of the first Fab molecule under a) the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) and the amino acid at position 123 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and wherein in the constant domain CH1 of the first Fab molecule under a) the amino acid at position 147 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index).

14. The T cell activating bispecific antigen binding molecule according to claim 10, wherein in the constant domain CL of the first Fab molecule under a) the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by arginine (R) (numbering according to Kabat), and wherein in the constant domain CH1 of the first Fab molecule under a) the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to Kabat EU index).

21. The T cell activating bispecific antigen binding molecule according to claim 1, further comprising

c) a third antigen binding moiety which specifically binds to the first antigen.

23. The T cell activating bispecific antigen binding molecule according to claim 21, wherein the third antigen binding moiety is identical to the first antigen binding moiety.

24. The T cell activating bispecific antigen binding molecule according to claim 21, wherein the first and the third antigen binding moiety specifically bind to a target cell antigen, and the second antigen binding moiety specifically binds to an activating T cell antigen, particularly CD3, more particularly CD3 epsilon.

25. The T cell activating bispecific antigen binding molecule according to claim 1, additionally comprising

d) an Fc domain composed of a first and a second subunit capable of stable association.

27. The T cell activating bispecific antigen binding molecule according to claim 1, wherein the first and the second antigen binding moieties are Fab molecules and the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety.

30. The T cell activating bispecific antigen binding molecule according to claim 25, wherein the first and the second antigen binding moieties are Fab molecules and the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc domain.

33. The T cell activating bispecific antigen binding molecule according to claim 25, comprising a third antigen binding moiety which specifically binds to the first antigen, wherein the third antigen binding moiety is a Fab molecule and is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain.

35. The T cell activating bispecific antigen binding molecule according to claim 25, comprising a third antigen binding moiety which specifically binds to the first antigen, wherein the first, second and third antigen binding moieties are Fab molecules and the first and the third antigen binding moiety are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain, and the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety.

37. The T cell activating bispecific antigen binding molecule according to claim 25, wherein the Fc domain is an IgG, specifically an IgG₁ or IgG₄, Fc domain.

38. The T cell activating bispecific antigen binding molecule according to claim 25, wherein the Fc domain is a human Fc domain.

39. The T cell activating bispecific antigen binding molecule according to claim 25, wherein the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain.

40. The T cell activating bispecific antigen binding molecule of claim 25, wherein the Fc domain is a human Fc domain, wherein in the CH3 domain of the first subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the CH3 domain of the first subunit which is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is positionable.

42. The T cell activating bispecific antigen binding molecule of claim 40, wherein in the CH3 domain of the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the CH3 domain of the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V), and optionally in the second subunit of the Fc domain additionally the threonine residue at position 366 is replaced with a serine residue (T366S) and the leucine residue at position 368 is replaced with an alanine residue (L368A) (numberings according to Kabat EU index).

43. The T cell activating bispecific antigen binding molecule of any one of claim 42, wherein in the first subunit of the Fc domain additionally the serine residue at position 354 is replaced with a cysteine residue (S354C) or the glutamic acid residue at position 356 is replaced with a cysteine residue (E356C), and in the second subunit of the Fc domain additionally the tyrosine residue at position 349 is replaced by a cysteine residue (Y349C) (numberings according to Kabat EU index).

46. The T cell activating bispecific antigen binding molecule according to claim 25, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor and/or effector function.

47. The T cell activating bispecific antigen binding molecule according to claim 25, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor and/or effector function and wherein said one or more amino acid substitution is at one or more position selected from the group of L234, L235, and P329 (Kabat EU index numbering).

48. The T cell activating bispecific antigen binding molecule according to claim 25, wherein each subunit of the Fc domain comprises the amino acid substitutions L234A, L235A and P329G (Kabat EU index numbering).

51. An isolated polynucleotide encoding the T cell activating bispecific antigen binding molecule of claim 1.

52. A vector, particularly expression vector, comprising an isolated polynucleotide encoding the T cell activating bispecific antigen binding molecule of claim 1.

53. A host cell comprising the polynucleotide(s) of claim 51.

54. A method of producing a T cell activating bispecific antigen binding molecule capable of specific binding to STEAP-1 and an activating T cell antigen, comprising the steps of a) culturing the host cell of claim 53 under conditions suitable for the expression of the T cell activating bispecific antigen binding molecule and b) optionally recovering the T cell activating bispecific antigen binding molecule.

55. A T cell activating bispecific antigen binding molecule produced by the method of claim 54.

56. A pharmaceutical composition comprising the T cell activating bispecific antigen binding molecule of claim 1 and a pharmaceutically acceptable carrier.

61. A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the T cell activating bispecific antigen binding molecule of claim 1 in a pharmaceutically acceptable form.

62. The method of claim 61, wherein said disease is cancer.

63. A method for inducing lysis of a target cell, comprising contacting a target cell with the T cell activating bispecific antigen binding molecule of claim 1 in the presence of a T cell.

4. (canceled)

11. (canceled)

12. (canceled)

15-20. -20. (canceled)

22. (canceled)

26. (canceled)

28. (canceled)

29. (canceled)

31. (canceled)

32. (canceled)

34. (canceled)

36. (canceled)

41. (canceled)

44. (canceled)

45. (canceled)

49. (canceled)

50. (canceled)

57-60. -60. (canceled)

64. (canceled)